Want to see DFTX full AI Analyst Report?
DFTX Stock Chart & Stats
$43.17
-$1.20(-2.78%)
At close: 4:00 PM EDT
$43.17
-$1.20(-2.78%)
Day’s Range― - ―
52-Week Range$8.70 - $49.70
Previous CloseN/A
Volume580.10K
Average Volume (3M)3.67M
Market Cap
$5.75B
Enterprise Value$4.16K
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$36.47M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Nov 05, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.44
Shares Outstanding134,366,940
10 Day Avg. Volume1,546,075
30 Day Avg. Volume3,668,603
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.60
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$66.29Price Target Upside53.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline With Multiple Imminent Pivotal ReadoutsMultiple, staggered Phase III readouts across MDD and GAD create a durable de-risking sequence for the lead program. Over 2–6 months these pivotal data points can materially change regulatory trajectory, partner interest, and commercialization planning beyond short-term market moves.
Breakthrough Therapy Designation In GADBreakthrough designation signals substantive clinical promise and secures more intensive FDA engagement. This structural regulatory advantage can accelerate development, clarify evidence requirements, and support faster review and labeling outcomes if pivotal data confirm benefit.
Material Balance Sheet Reinforcement And Extended RunwayA large equity raise plus existing cash materially bolsters financial flexibility for late‑stage execution and launch preparedness. This durable capital cushion reduces near‑term solvency risk and funds regulatory, commercial, and R&D investments while clinical programs mature.
Bears Say
Pre-revenue Commercial Profile With Large Operating LossesDFTX remains pre-commercial with no product revenue and sharply widening losses. Structural profitability will depend on regulatory approval and successful commercialization of DT120 or other assets, so the company faces an enduring earnings gap until product revenues materialize.
Accelerating Cash Burn And Negative Free Cash FlowNegative operating and free cash flow have accelerated materially year over year, consuming capital and pressuring sustainability. Even with recent financing, persistent burn rates imply ongoing financing needs or program cuts unless revenues or dramatic cost reductions emerge.
High Dependence On Pivotal Readouts And Regulatory/payer UncertaintyThe business case is materially contingent on a few late‑stage outcomes and subsequent regulatory/payer decisions. Trial design/placebo risks, potential FDA discussions and reimbursement uncertainty create persistent binary execution risk that will dictate commercialization viability.
Definium Therapeutics News
DFTX FAQ
What was Definium Therapeutics, Inc.’s price range in the past 12 months?
Definium Therapeutics, Inc. lowest stock price was $8.70 and its highest was $49.70 in the past 12 months.
What is Definium Therapeutics, Inc.’s market cap?
Definium Therapeutics, Inc.’s market cap is $5.75B.
When is Definium Therapeutics, Inc.’s upcoming earnings report date?
Definium Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Definium Therapeutics, Inc.’s earnings last quarter?
Definium Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$0.541 by -$0.899.
Is Definium Therapeutics, Inc. overvalued?
According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued.
Does Definium Therapeutics, Inc. pay dividends?
Definium Therapeutics, Inc. does not currently pay dividends.
What is Definium Therapeutics, Inc.’s EPS estimate?
Definium Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Definium Therapeutics, Inc. have?
Definium Therapeutics, Inc. has 134,366,940 shares outstanding.
What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?
Definium Therapeutics, Inc. reported an EPS of -$1.44 in its last earnings report, missing expectations of -$0.541. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DFTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Definium Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.29 (53.55% Upside)
$66.29 (53.55% Upside)
Blogger Sentiment
Bullish
DFTX Sentiment 96%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
336.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
319.82%
Trailing 12-Months
Company Description
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
DFTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DFTX earnings summariesDFTX Stock 12 Month Forecast
Average Price Target
$66.29
▲(53.55% Upside)
Technical Analysis
AnaptysBio
―
Enliven Therapeutics
―
Tyra Bioscience
―
Biohaven Ltd.
―
Inhibrx Biosciences Inc
―
Ownership Overview
2.29% Insiders
7.93% Mutual Funds
10.72% Other Institutional Investors
69.40% Public Companies and Individual Investors